Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
Parkinson disease
aromatase inhibitors
breast cancer
tamoxifen
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 06 2022
15 06 2022
Historique:
revised:
23
02
2022
received:
06
12
2021
accepted:
14
03
2022
pubmed:
2
4
2022
medline:
24
5
2022
entrez:
1
4
2022
Statut:
ppublish
Résumé
Current guidelines recommend the treatment of hormone receptor-positive breast cancer with aromatase inhibitors (AIs) and tamoxifen in the adjuvant setting. Some observational studies have raised concerns that tamoxifen may be associated with an increased risk of Parkinson disease (PD). However, no studies have directly compared the risk of PD between AIs and tamoxifen in women diagnosed with breast cancer. Using the UK Clinical Practice Research Datalink, the authors assembled a cohort of women newly diagnosed with breast cancer and newly treated with either AIs or tamoxifen between January 1, 1995, and December 31, 2017. Patients were followed 1 year after treatment initiation (ie, a 1-year lag) until an incident diagnosis of PD or were censored at death from any cause, the date of transfer out of the practice, or the end of the study period (December 31, 2018). Cox proportional hazards models with inverse probability of treatment weights were used to estimate weighted hazard ratios (HRs) and 95% confidence intervals (CIs) for PD comparing AIs with tamoxifen and accounting for more than 30 confounders. In all, 30,140 women with nonmetastatic breast cancer were identified: 13,838 initiated AIs, and 16,302 initiated tamoxifen. Compared with tamoxifen, AIs were not associated with an increased risk of PD (HR, 0.94; 95% CI, 0.60-1.47). Consistent results were observed across all secondary and sensitivity analyses. In this large observational study, the use of AIs, in comparison with tamoxifen, was not associated with an increased risk of PD in women diagnosed with nonmetastatic breast cancer in a real-world setting. Previous studies have indicated that tamoxifen may increase the risk of Parkinson disease in the treatment of breast cancer. However, no studies have directly compared the risk of Parkinson disease between aromatase inhibitors and tamoxifen. This study included 30,140 women diagnosed with breast cancer and treated with aromatase inhibitors or tamoxifen. Overall, compared with tamoxifen, aromatase inhibitors were not associated with an increased risk of Parkinson disease in women diagnosed with breast cancer. This study provides an important addition to the comparative safety profile of aromatase inhibitors and tamoxifen in the treatment of breast cancer.
Sections du résumé
BACKGROUND
Current guidelines recommend the treatment of hormone receptor-positive breast cancer with aromatase inhibitors (AIs) and tamoxifen in the adjuvant setting. Some observational studies have raised concerns that tamoxifen may be associated with an increased risk of Parkinson disease (PD). However, no studies have directly compared the risk of PD between AIs and tamoxifen in women diagnosed with breast cancer.
METHODS
Using the UK Clinical Practice Research Datalink, the authors assembled a cohort of women newly diagnosed with breast cancer and newly treated with either AIs or tamoxifen between January 1, 1995, and December 31, 2017. Patients were followed 1 year after treatment initiation (ie, a 1-year lag) until an incident diagnosis of PD or were censored at death from any cause, the date of transfer out of the practice, or the end of the study period (December 31, 2018). Cox proportional hazards models with inverse probability of treatment weights were used to estimate weighted hazard ratios (HRs) and 95% confidence intervals (CIs) for PD comparing AIs with tamoxifen and accounting for more than 30 confounders.
RESULTS
In all, 30,140 women with nonmetastatic breast cancer were identified: 13,838 initiated AIs, and 16,302 initiated tamoxifen. Compared with tamoxifen, AIs were not associated with an increased risk of PD (HR, 0.94; 95% CI, 0.60-1.47). Consistent results were observed across all secondary and sensitivity analyses.
CONCLUSIONS
In this large observational study, the use of AIs, in comparison with tamoxifen, was not associated with an increased risk of PD in women diagnosed with nonmetastatic breast cancer in a real-world setting.
LAY SUMMARY
Previous studies have indicated that tamoxifen may increase the risk of Parkinson disease in the treatment of breast cancer. However, no studies have directly compared the risk of Parkinson disease between aromatase inhibitors and tamoxifen. This study included 30,140 women diagnosed with breast cancer and treated with aromatase inhibitors or tamoxifen. Overall, compared with tamoxifen, aromatase inhibitors were not associated with an increased risk of Parkinson disease in women diagnosed with breast cancer. This study provides an important addition to the comparative safety profile of aromatase inhibitors and tamoxifen in the treatment of breast cancer.
Substances chimiques
Antineoplastic Agents, Hormonal
0
Aromatase Inhibitors
0
Tamoxifen
094ZI81Y45
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2339-2347Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 American Cancer Society.
Références
Rozeboom B, Dey N, De P. ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res. 2019;9:2821-2831.
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37:423-438. doi:10.1200/jco.18.01160
National Institute for Health and Care Excellence. Early and Locally Advanced Breast Cancer: Diagnosis and Management. National Institute for Health and Care Excellence; 2018.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1674. doi:10.1093/annonc/mdz189
Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341-1352. doi:10.1016/S0140-6736(15)61074-1
Kelly E, Lu CY, Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. J Clin Pharm Ther. 2015;40:76-82. doi:10.1111/jcpt.12227
Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299-1309. doi:10.1093/jnci/djr242
Aydiner A. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast. 2013;22:121-129. doi:10.1016/j.breast.2013.01.014
Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011;125:13-22. doi:10.1016/j.jsbmb.2011.02.001
Lum SS, Woltering EA, Fletcher WS, Pommier RF. Changes in serum estrogen levels in women during tamoxifen therapy. Am J Surg. 1997;173:399-402. doi:10.1016/s0002-9610(97)00072-x
Lee YH, Cha J, Chung SJ, et al. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naive postmenopausal Parkinson's disease. Sci Rep. 2019;9:10531. doi:10.1038/s41598-019-47026-6
Cerri S, Mus L, Blandini F. Parkinson's disease in women and men: what's the difference? J Parkinsons Dis. 2019;9:501-515. doi:10.3233/jpd-191683
Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry. 2004;75:637-639. doi:10.1136/jnnp.2003.020982
Poewe W, Seppi K, Tanner CM, et al. Parkinson Disease. Nat Rev Dis Primers. 2017;3:17013. doi:10.1038/nrdp.2017.13
Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419-425.
Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997;350:1097-1099. doi:10.1016/s0140-6736(97)04248-7
Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44:827-836. doi:10.1093/ije/dyv098
Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302:766-768. doi:10.1136/bmj.302.6779.766
Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23:686-689.
Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128-e136. doi:10.3399/bjgp10X483562
Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221-228. doi:10.1007/s40471-015-0053-5
Giorgianni F, Ernst P, Dell'Aniello S, Suissa S, Renoux C. Beta 2-agonists and the incidence of Parkinson disease. Am J Epidemiol. 2020;189:801-810. doi:10.1093/aje/kwaa012
Hernan MA, Logroscino G, Rodriguez LA. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol. 2004;251(suppl 7):vII14-vII17. doi:10.1007/s00415-004-1705-4
Renoux C, Dell'Aniello S, Khairy P, et al. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol. 2016;82:461-472. doi:10.1111/bcp.12964
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661-3679. doi:10.1002/sim.6607
Wyss R, Girman CJ, LoCasale RJ, Brookhart AM, Sturmer T. Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiol Drug Saf. 2013;22:77-85. doi:10.1002/pds.3356
Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014;49:1701-1720. doi:10.1111/1475-6773.12182
Hernán MA, Robins JM. Causal Inference: What If. Chapman & Hall/CRC; 2020.
Howe CJ, Cole SR, Lau B, Napravnik S, Eron JJ Jr. Selection bias due to loss to follow up in cohort studies. Epidemiology. 2016;27:91-97. doi:10.1097/ede.0000000000000409
Rubin D. Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons; 1987.
Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health (Oxf). 2014;36:684-692. doi:10.1093/pubmed/fdt116
Lin HF, Liao KF, Chang CM, Lin CL, Lai SW. Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan. Eur J Clin Pharmacol. 2018;74:99-107. doi:10.1007/s00228-017-2341-0
Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer. 2016;7:1281-1294. doi:10.7150/jca.13141
Hong CT, Chan L, Hu CJ, Lin CM, Hsu CY, Lin MC. Tamoxifen and the risk of Parkinson's disease in female patients with breast cancer in Asian people: a nationwide population-based study. J Breast Cancer. 2017;20:356-360. doi:10.4048/jbc.2017.20.4.356
Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL. Risk of Parkinson's disease after tamoxifen treatment. BMC Neurol. 2010;10:23. doi:10.1186/1471-2377-10-23
Montastruc F, Khosrow-Khavar F, de Germay S, et al. Tamoxifen and the risk of Parkinsonism: a case/non-case study. Eur J Clin Pharmacol. 2018;74:1181-1184. doi:10.1007/s00228-018-2496-3
Lonning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011;22:503-514. doi:10.1093/annonc/mdq337
Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids. 2007;72:381-405. doi:10.1016/j.steroids.2007.02.003
Wang P, Li J, Qiu S, Wen H, Du J. Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studies. Neuropsychiatr Dis Treat. 2015;11:59-66. doi:10.2147/ndt.s69918
Barrett-Connor E, Goodman-Gruen D. Cognitive function and endogenous sex hormones in older women. J Am Geriatr Soc. 1999;47:1289-1293. doi:10.1111/j.1532-5415.1999.tb07427.x
Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009;27:3192-3197. doi:10.1200/jco.2008.18.6213
Bajetta E, Martinetti A, Zilembo N, et al. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol. 2002;13:1059-1066. doi:10.1093/annonc/mdf083
Baumgart J, Nilsson K, Stavreus Evers A, et al. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients. Climacteric. 2014;17:48-54. doi:10.3109/13697137.2013.800039
Gervais NJ, Remage-Healey L, Starrett JR, Pollak DJ, Mong JA, Lacreuse A. Adverse effects of aromatase inhibition on the brain and behavior in a nonhuman primate. J Neurosci. 2019;39:918-928. doi:10.1523/jneurosci.0353-18.2018
Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048. doi:10.1093/jnci/djv048
National Institute for Clinical Excellence. Improving Outcomes in Breast Cancer: Manual Update. National Institute for Clinical Excellence; 2002.
Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015;6:231-239. doi:10.4331/wjbc.v6.i3.231